In this article CVS Follow your favorite stocks CREATE FREE ACCOUNT FTC Chairwoman Lina Khan testifies during the House Appropriations Subcommittee on Financial Services and General Government hearing titled "Fiscal Year 2025 Request for the Federal Trade Commission," in Rayburn Building on Wednesday, May 15, 2024. Tom Williams | Cq-roll Call, Inc. | Getty Images CVS Health is demanding Federal Trade Commission Chairwoman Lina Khan and two other commissioners recuse themselves from a lawsuit accusing the company and other drug middlemen of boosting their profits while inflating insulin costs for Americans.
In a 23-page motion filed Tuesday night with the FTC, CVS argued that all three commissioners have "a lengthy track record of making public statements that indicate serious bias" against the company and other drug middlemen. The company accused Khan, as well as commissioners Alvaro Bedoya and Rebecca Kelly Slaughter, of incorrectly asserting that so-called pharmacy benefit managers are "price gougers" that hold significant control over the pricing and access to drugs like insulin. CVS said those statements demonstrate that the commissioners have "prejudged this matter," so their participation in the case "violates due process.
" "If the opposite of 'complete fairness' is 'blatant bias,' the Three Commissioners would easily satisfy even that standard," CVS wrote. The FTC on Wednesday did not immediately respond to CNBC's request for comment on the motion. Other corporate gian.